Sumitomo Pharma

4506 · TSE

Public Market Listing

4506TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Sumitomo Pharma are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(7 total)
7Total Assets
3Approved
1Phase 3 / Filed
3Phase 1–2 / Early
8Diseases
Quick filter:
Showing 7 of 7 assets
Target & Modality
Approved
norepinephrine precursorSmall molecule
Parkinson's DiseaseNeurogenic Orthostatic Hypotension
Approved
Voltage-gated sodium channelSmall molecule
Epilepsy
Focal Onset Seizures
Approved
Dopamine D2/D3 receptor + 5-HT7 receptor · Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Depression
Vildagliptin(Galvus)
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Phase 1/2
Menin-KMT2A protein-protein interactionSmall molecule
Acute Myeloid Leukemia
Phase 1/2
Allogeneic iPSC-derived dopaminergic progenitor cellsCell therapy
Parkinson's Disease
Phase 1/2
Checkpoint kinase 1 (CHK1)Small molecule
Non-Small Cell Lung Cancer

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
EnzomenibPhase 1/2Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Est. primary completion 2027-06-30 · NCT04988555 · CT.gov ↗
What to watch
2028 (1)
December 2028 (1)
SMP3124LPPhase 1/2Solid Tumor
Est. primary completion 2028-12 · NCT06526819 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Raguneprocel (Amchepry)Phase 1/2Parkinson's Disease
Est. primary completion 2030-12-15 · NCT06753331 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 February 2025WithdrawalApomorphine sublingual film (Kynmobi)FDA withdraws approval of NDA 210875 (Federal Register 2025-00743)
US, FDA · Source ↗
June 2023WithdrawalApomorphine sublingual film (Kynmobi)Sunovion voluntarily withdraws KYNMOBI from the US and Canadian markets
US, FDA · Sunovion Pharmaceuticals Inc. (Sumitomo Pharma) · Source ↗

Financial reports

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$3.0B$289M——report ↗